Detecting and profiling measurable residual disease in multiple myeloma patients
Official title: Detect and Profile Multiple Myeloma Measurable Residual Disease (MRD )Prognostics for Monitoring Post-transplant Multiple Myeloma (MM) Patients Receiving Maintenance Therapy.
Run by Sir Mortimer B. Davis - Jewish General Hospital · NCT05530096 · Data updated 2026-11-12
This study is testing a new way to check for leftover cancer cells in multiple myeloma patients who are in remission after a transplant to see how well their treatment is working.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | Sir Mortimer B. Davis - Jewish General Hospital Academic / other |
| Locations | 1 site (Montreal, Quebec) |
| Status | Recruiting |
| Started | May 1, 2024 |
| Main results expected | September 2027 |
| Study ends | September 2028 |
| Registry record updated | April 3, 2025 |
| Trial ID | NCT05530096 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with a confirmed diagnosis of multiple myeloma who are transplant-eligible and in their first remission.
✕Probably not a fit
Patients who do not meet the inclusion criteria, such as those not in remission or not eligible for transplant, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to detect and profile measurable residual disease (MRD) in patients with multiple myeloma who are in their first remission and receiving maintenance therapy post-transplant. It utilizes Telo Genomics Technology alongside standard care to monitor MRD levels, which are crucial for assessing treatment efficacy and disease progression. The study will collect deidentified demographic and clinical follow-up data to enhance understanding of MRD prognostics in this patient population.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management of multiple myeloma, potentially enhancing patient outcomes.
How similar studies have gone: Other studies have shown promise in using similar methodologies for monitoring MRD in multiple myeloma, indicating a potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmed MM diagnosis * Transplant eligible patients in a first remission * Known MRD level detected by ClonoSeq (other IMWG recognized methodologies can be also employed) * Availability of deidentified patient's demographic and clinical follow up data * Receiving standard of care treatment * Able to provide informed consent Exclusion Criteria: * Failure to meet inclusion criteria
Where it's running
-
Jewish General Hospital
Montreal, Quebec, Canada Recruiting
Study contacts
- Principal investigator: Rayan Kaedbey — Sir Mortimer B. Davis - Jewish General Hospital
- Study coordinator: Rayan Kaedbey, MD FRCPC
- Email: rayan.kaedbey.med@ssss.gouv.qc.ca
- Phone: 514-340-8222
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
6MW5311 in adults with relapsed or refractory blood cancers
This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
-
Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma
In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.
-
Exercise phenotyping before chemotherapy in newly diagnosed multiple myeloma
This observational study tests whether some newly diagnosed multiple myeloma patients with normal resting heart function already show limited exercise capacity, and whether that limitation relates to subtle heart tissue changes and future heart-related outcomes.
-
SMS text check-ins to track symptoms for people with plasma cell disorders
This study tests whether daily SMS symptom prompts are feasible and acceptable for adults starting treatment for multiple myeloma or AL amyloidosis.
-
Cevostamab with Pomalidomide and Dexamethasone after BCMA-directed CAR T therapy in multiple myeloma
This study tests if Cevostamab combined with pomalidomide and dexamethasone can help people with multiple myeloma who have already had CAR T therapy and several prior treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.